

06-19-00

A

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
2331/111

Total Pages in this Submission

44

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

SYSTEM AND METHOD FOR QUANTITATIVE ASSAY FOR LOW ABUNDANCE MOLECULES

and invented by:

John C. Cheronis
David Trollinger

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. ☐ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 33 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☒ Cross References to Related Applications (if applicable)
 - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. ☐ Reference to Microfiche Appendix (if applicable)
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☒ Brief Description of the Drawings (if drawings filed)
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☐ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
2331/111

Total Pages in this Submission

44

Application Elements (Continued)

3. ☒ Drawing(s) (when necessary as prescribed by 35 USC 113)

a. ☐ Formal

b. ☒ Informal

Number of Sheets

4

4. ☒ Oath or Declaration

a. ☐ Newly executed (original or copy)

☒ Unexecuted

b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)

c. ☒ With Power of Attorney ☐ Without Power of Attorney

d. ☐ DELETION OF INVENTOR(S)

Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5. ☐ Incorporation By Reference (usable if Box 4b is checked)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Computer Program in Microfiche

7. ☐ Genetic Sequence Submission (if applicable, all must be included)

a. ☐ Paper Copy

b. ☐ Computer Readable Copy

c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers (cover sheet & documents)

9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee)

10. ☐ English Translation Document (if applicable)

11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations

12. ☐ Preliminary Amendment

13. ☒ Acknowledgment postcard

14. ☒ Certificate of Mailing

☐ First Class

☒ Express Mail (Specify Label No.): EL543 498 745US

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
2331/111

Total Pages in this Submission

44

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. ☐ Small Entity Statement(s) - Specify Number of Statements Submitted: _____

17. ☐ Additional Enclosures (please identify below):

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	44	- 20 =	24	x \$9.00	\$216.00
Indep. Claims	4	- 3 =	1	x \$39.00	\$39.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$345.00
OTHER FEE (specify purpose) _____					\$0.00
TOTAL FILING FEE					\$600.00

- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☐ Credit any overpayment.
- ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: June 16, 2000



Signature

Harriet M. Strimpel, D. Phil.
Reg. No. 37,008 Customer No: 002101
BROMBERG & SUNSTEIN LLP
125 Summer Street
Boston, Massachusetts 02110
(617) 443-9292
(617) 443-0004 FAX

CC:

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)			Docket No. 2331/111
Applicant(s): Cheronis et al.			
Serial No. unassigned	Filing Date herewith	Examiner unassigned	Group Art Unit unassigned
Invention: SYSTEM AND METHOD FOR QUANTITATIVE ASSAY FOR LOW ABUNDANCE MOLECULES			
<div style="text-align: right;">jc832 U.S. PTO 09/595720 06/16/00</div>			
<p>I hereby certify that this <u>new utility patent application transmittal and enclosures referred to herein</u> (Identify type of correspondence)</p> <p>is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on <u>June 16, 2000</u> (Date)</p> <div style="text-align: right;"><p><u>Harriet M. Strimpel, D. Phil.</u> (Typed or Printed Name of Person Mailing Correspondence)</p><p><u>Harriet Strimpel</u> (Signature of Person Mailing Correspondence)</p><p><u>EL543 498 745US</u> (<i>"Express Mail"</i> Mailing Label Number)</p></div>			
<p>Note: Each paper must have its own certificate of mailing.</p>			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket: 2331/111

**SYSTEM AND METHOD FOR QUANTITATIVE ASSAY FOR LOW
ABUNDANCE MOLECULES**

Inventors: John C. Cheronis
24011 Pleasant Road
Conifer, CO 80433

David Trollinger
5375 Desert Mountain Court
Boulder, CO 80301

Prepared by:

Bromberg & Sunstein LLP
125 Summer Street
Boston, MA 02110
Telephone: 617/443-9292
Facsimile: 617/443-0040

SYSTEM AND METHOD FOR QUANTITATIVE ASSAY FOR LOW
ABUNDANCE MOLECULES

5

Related Applications

This application gains priority from provisional patent application Serial No. 60/139,647, filed June 17, 1999 and provisional patent application Serial No. 60/139,697 filed June 17, 1999, both provisional applications herein incorporated by reference.

Technical Field

10

Embodiments of the invention relate to quantitative assays for low abundance molecules including antibodies to measure an antibody response in a subject.

Background Art

15

The sensitivity of assays for measuring target molecules in a sample is generally constrained by the threshold of detection provided by the selected method. For example, typical detection systems for proteins employ an antibody specific for that protein immobilized on a solid support matrix. The matrix is typically a nitrocellulose filter, and the detection and quantification is based on antibody-protein binding such that the target protein is retained on the filter and then quantitated (usually by detection of a fluorescent or radioactive moiety present on the immobilized antibody, or incorporated in the target molecule). However, limitations in threshold detection levels exist in the art as it is presently known. For example, an antibody that binds specifically to a known protein can have a K_D for that protein that is in the range of 10^{-9} molar concentration. If the protein is present at a concentration below the range of the K_D , the antibody is not useful for such detection, since the antibody-antigen complex will not form to an appreciable extent and thus the target protein will not be retained on the solid support matrix. Further, formation of even one or a few antibody-antigen complexes cannot be detected in the presence of an excess of other materials. Techniques such as MALDI-TOF and similar analyses require expensive detection and analytical instrumentation which are not commonly available in a medical environment,

20

25

and are complicated to operate on a high throughput basis.

Aptamers have been developed to bind specifically to target molecules for purposes of identifying the molecules for disease analysis. PCT application number WO 99-07724, by Nextar Pharmaceuticals, Inc., authored by Heilig and Gold, "Nucleic Acid Ligands for Blood-Brain and Cerebrospinal Fluid-Blood Barriers by Tissue SELEX," published February 18, 1999, discloses use of the SELEX system of obtaining a nucleic acid that has a sequence capable of binding a target protein with high affinity and specificity, in this case for components of cerebrospinal fluid and the blood-brain barrier. The nucleic acid having affinity for a target is known as an "aptamer"; aptamers have been developed for a variety of different types of target materials. See also, for example, PCT application number WO 95/07364, by Nexagen, Inc., authored by Gold et al., "Nucleic Acid Ligands and Improved Methods for Producing the Same," published March 16, 1995; and PCT application number WO 91/19813, by University of Colorado Foundation, authored by Gold and Tuerk, "Nucleic Acid Ligands," published December 26, 1991. The foregoing publications and the references cited therein are hereby incorporated herein by reference.

These methods typically use proteins and other molecules as the starting point, and then seek to identify, select, and enrich aptamers capable of binding the target molecules. Of particular interest to those using such methods is the identification of nucleic acid aptamers capable of binding molecules not previously known to bind nucleic acids.

Quantification of nucleic molecules has been achieved using Quantitative Polymerase Chain Reaction (QPCR), Quantitative Competitive Reverse Transcription-PCR [QC (RT)-PCR] or Real Time Detection 5'-Nuclease-PCR (RTDN-PCR; also known as TaqMan RT-PCR), is limited because of its focus on detection of nucleic acids. These techniques have been used to detect and measure concentrations of viable *Cryptosporidium parvum* oocytes present in environmental water concentrates, based on detection of DNA generated with RT-PCR from mRNA obtained from oocytes using oligo(T)₂₅ magnetic beads ("Sensitive and Rapid Detection of Viable *Giardia* Cysts and *Cryptosporidium parvum* Oocytes in Large-Volume Water Samples with Wound Fiberglass Cartridge Filters and Reverse Transcription-PCR," C. Kauener and T. Stinear, *Appl. Environ. Microbiol.*, 1998, 64(5):1743-1756).

However, detection is limited by the necessity of obtaining mRNA, an inherently unstable and short-lived species ($t_{1/2}$ values in cells are typically less than 3 minutes for any given mRNA.)

It is also known in the art to correlate the concentration of a protein in a sample tissue to its mRNA expression, such as thrombopoietin in bone marrow cells, by use of TaqMan

5 real-time quantitative RT-PCR ("Concentrations of Thrombopoietin in Bone Marrow in Normal Subjects and in Patients with Idiopathic Thrombocytopenic Purpura, Aplastic Anemia, and Essential Thrombocythemia Correlate With Its mRNA Expression of Bone Marrow Stromal Cells," Y. Hirayama et al., *Blood*, 1998, 92(1): 46-52). This quantitative replicative method relies on the presence of a 5'-nuclease assay in the RT-PCR reactions, 10 wherein a probe (the TaqMan probe) specific for an aptamer directed to the target protein, contains a fluorescent moiety such as 6-carboxyfluorescein (FAM) on the 5'-end, and a phosphate-capped quencher fluor moiety such as 6-carboxytetramethylfluorescein (TAMRA) on the 3'-end of the probe. As amplification of the mRNA for the target protein proceeds, the intensity of fluorescence of the FAM moiety increases as a function of time and mRNA 15 concentration due to 5'-endonuclease cleavage of the probe, releasing more and more FAM moiety into the solution.

Again, this method is limited by the requirement for mRNA, and also is limited in that the concentration of thrombopoietin calculated in the sample is only a correlation to mRNA expression, it is not a measurement of thrombopoietin itself, or a measurement of a molecule 20 which can be related directly to target protein concentration.

In other prior art, it is known to use either TaqMan RT-PCR coupled with an ABI Prism 7700 Sequence Detection System, or Competitive PCR for quantification of DNA from a bacterial pathogen in the sputum of patients during treatment (see "Comparison of the ABI 7700 System (TaqMan) and Competitive PCR for Quantification of IS6110 DNA in 25 Sputum During Treatment of Tuberculosis," Desjardin, L.e. et al., *J. Clin. Microbiol.* 1998, 36(7):1964 - 1976). The two methods were found to be reproducible and accurate, and comparable in terms of detection limits. However, both methods were limited by poor correlation between quantity of *M. tuberculosis* DNA determined and the number of

cultivable bacilli in the sputum specimen.

Quantitative replicative methods are thus focused on measurement of nucleic acids or its expression to determine protein concentration. Methods such as SELEX for generation, selection, and enrichment of nucleic acid aptamers are focused on the aptamer itself, e.g. finding aptamers which bind to unusual target molecules not previously known to bind nucleic acids, or finding aptamers which distinguish molecules of close chemical make-up, such as aptamers which can distinguish caffeine and theophyllin - molecules in the purine family which differ only in the presence or absence of a methyl group. In other methods, the nucleic acid aptamers are designed to prevent antibody interaction with its target receptor cell, in efforts to inhibit the allergic response (see for example, PCT application number WO 96/10576, by Nextar Pharmaceuticals, Inc. authored by Wiegand et al., "High Affinity Oligonucleotide Ligands to Immunoglobulin E (IgE)" published April 11, 1996).

Summary

Embodiments of the invention relate to the detection of low abundance molecules using a novel approach that relies on aptamers to bind the target molecule and determining the concentration of low abundance molecules based on the concentration of aptamers.

A specific embodiment of the invention includes a method for quantitatively assaying one or more target molecules in a first sample that includes: adding to the first sample, a preparation of a nucleic acid aptamer specific for each target molecule; allowing substantially all of the target molecules in the first sample to bind with the aptamers; separating unbound aptamers from the first sample by contacting the sample with immobilized ligands wherein the ligands bind to the unbound aptamers; recovering a second sample containing the aptamer bound to target molecules; and using a quantitative replicative procedure to determine a quantity related to the concentration of the aptamer in the second sample and therefore related to the concentration of target molecules in the first sample.

In preferred embodiments, the nucleic acid aptamer is selected from the group consisting of natural or synthetic single-stranded DNA, double-stranded DNA, single-stranded RNA, double-stranded RNA and chemical modifications thereof. The target molecules may be present in the sample at molar concentrations less than their dissociation

constants with respect to the aptamers and may be low abundance molecules. The target molecules may include biological macromolecules which may be selected from the group consisting of a protein, a lipid, a polysaccharide or combinations thereof. The target molecules may include small organic molecules and furthermore may be selected from a group consisting of antibiotics, vitamins, steroids, and pesticides. The target molecules may include inorganic molecules, more particularly metals, more particularly metal ions, metal oxides, and metal complexes. The target molecules may also be an antibody, more particularly IgE, more particularly a plurality of antibody molecules belonging to different subclasses characterized by a difference in the hypervariable region of the antibody, more particularly a subclass of an antibody having a characteristic hypervariable region. In a preferred embodiment, the aptamer binds to a constant region of the antibody.

In a preferred embodiment, the first sample is obtained from an animal subject, more particularly organ tissue, muscle tissue, bone tissue, connective tissue, fetal, placental, lymphatic tissue, vascular tissue, neuronal tissue. The sample may be a biological fluid selected from blood, lymph, urine, sputum, joint including spinal fluid, and saliva. The first sample may be an environmental sample, including samples obtained from a plant, water, food beverages including milk, and industrial waste.

In a preferred embodiment, the immobilized ligand is immobilized on a support matrix selected from the group consisting of resins, beads, including magnetic beads, gels, cellulose and silica. More particularly, the immobilized ligand is immobilized on an affinity column. The immobilized ligand may be the constant region of the antibody for removing unbound aptamer from the sample.

In a preferred embodiment, the quantitative replicative procedure is a quantitative polymerase chain reaction. The method may further include measuring the amount of aptamer bound to the target molecule further including denaturing the aptamer so as to separate the nucleic acid from the target molecules. In further embodiments, oligonucleotide primers are added to the sample after denaturing the aptamer from the target molecules.

In a preferred embodiment, a method is provided as described above in which the target molecules are antibodies and the second sample contains antibody-bound aptamer, the second sample being divided into a plurality of aliquots, a first aliquot of the second sample

being assayed using a quantitative replicative technique to determine an amount of antibody in the first sample. Moreover, the method may further include the steps of contacting a second aliquot of the second sample with an immobilized ligand for binding an antibody with a first hypervariable region; wherein the antibody with a first hypervariable region is one of the target molecules in the first sample; recovering a third sample containing the aptamer

5 bound to target molecules excluding the antibody with the first hypervariable region; assaying the aptamer concentration in the third sample using the quantitative replicative technique, so as to determine a difference in an amount of aptamer in the second sample and the third sample; and obtaining a measure of an amount of the antibody with the first hypervariable region in the first sample from the difference. Alternatively, the method may

10 include the steps of: (a) contacting a plurality of aliquots of the second sample with an immobilized ligand wherein the ligand is immobilized by attachment to a substrate in a single chamber, or to multiple substrates wherein each substrate is contained in a separate chamber, each immobilized ligand having a specificity for an antibody with a different hypervariable site; (b) recovering a third sample containing the aptamer bound to target molecules

15 excluding the antibody bound to immobilized ligand; (c) assaying the aptamer concentration in the third sample using the quantitative replicative technique, so as to determine a difference in an amount of aptamer in the second sample and the third sample; and (d) obtaining a measure of the antibody with the hypervariable region in the first sample from the difference.

20 In a specific embodiment, a method is provided that includes: quantitatively evaluating *in vitro* an antibody response of a subject to an antigen, the method including obtaining a sample from the subject and an aptamer for binding generally to all antibodies of a common class; allowing substantially all of such antibodies in the sample to bind the aptamer in a common class mixture, so that the common class mixture includes antibody-

25 aptamer complexes; using antigen-antibody affinity binding to separate from an aliquot of the common class mixture those of the antibody-aptamer complexes having antibodies specific to the antigen, to produce (i) an antigen-specific antibody-aptamer complex and (ii) a difference mixture; and, using a quantitative replicative procedure to determine a quantity

related to the concentration of the antigen-specific antibody-aptamer complex relative to the concentration of the antibody-aptamer complexes in the common class mixture, and therefore related to the response of the subject to the antigen.

In a specific embodiment of the invention, a method is provided for quantitatively evaluating *in vitro* the response of a subject to a plurality of different antigens, the method
5 that includes: obtaining a sample from the subject and adding an aptamer for binding generally to all antibodies of a common class in the tissue; allowing substantially all of such antibodies in the sample to form a complex with the aptamer in a common class mixture, so that the common class mixture includes antibody-aptamer complexes; using antigen-antibody affinity binding to separate, from each of a plurality of aliquots of the common class
10 mixture, those of the antibody-aptamer complexes having antibodies specific to a different one of the antigens, to produce with respect to each different antigen (i) an antigen-specific antibody-aptamer complex and (ii) a difference mixture; and, using a quantitative replicative procedure to determine a quantity related to the concentration of each different antigen-specific antibody-aptamer complex relative to the concentration of the antibody-aptamer
15 complexes in the common class mixture, and therefore related to the response of the subject's tissue to each of the different antigens.

In a preferred embodiment, a kit is provided for determining the allergic response of a subject to an allergen, that includes: an aptamer specific for a common class of IgE and a plurality of aptamers specific for individual allergens; a plurality of reaction chambers for
20 holding individual aliquots of a sample taken from the subject after binding the common class of antibody and removing unbound aptamer; an immobilized antibody for binding unbound aptamer of the common class prior to dividing the sample into aliquots, and allergen for binding specific antibodies; and, means for quantitatively replicating the aptamers of the common class of IgE and for the aptamer-IgE complexes not bound to the
25 allergen.

Brief Description of the Drawings

The foregoing features of the invention will be more readily understood by reference to the following detailed description, taken with reference to the accompanying drawings, in

which:

Fig. 1 illustrates schematically an intermediate stage after addition of aptamers to a sample in a reaction vessel to determine the presence of low abundance molecules by allowing aptamer to bind target molecules.

Fig. 2 shows schematically the effect after the materials in Fig.1 are further treated to
5 remove remaining uncomplexed aptamers.

Fig. 3 illustrates schematically an intermediate stage after the addition of aptamers to a sample to determine the amount of different antibodies in the sample, the sample being analyzed to detect antibody-aptamer complexes in a common class mixture; and

Fig. 4 shows schematically the separation of antigen-specific antibody-aptamer
10 complexes from aliquots of the common class mixture.

Detailed Description of Embodiments of the Invention

Embodiments of the invention allow the amount of target molecules in multiple samples to be determined using quantitative replicative techniques to measure the amount of
15 aptamer bound to the target molecule and hence to determine the amount of target molecule. Novel features of the methods described herein include the use of a single entity that is both the binding entity and the reporter molecule. Moreover, the binding entity has the advantageous feature of having a “tight” binding constant of the order of 10^{-11} to 10^{-12} molar.

Quantification of target molecules present in very low abundance in the sample may
20 be determined down to a theoretical single target molecule because the method does not require the target molecule be present in the sample at concentrations greater than the K_D value of the target molecule for its specific aptamer. Thus, the methods provided herein can be used to detect low abundance molecules in the environment or in a subject or elsewhere.

To illustrate the utility of embodiments of the invention, the method may be used to
25 diagnose the presence of a protein product of a cell or a tissue at an earlier stage of development, that might be indicative of a pathological condition such as a tumor or an infection. For example, a small number of molecules indicative of malformation of the fetus such as α -fetoprotein, indicative of defects in the central nervous, system may be detected.

Alternatively, tumor markers such as nestin, indicative of metastasis of a melanoma, can be detected using the methods described herein. The methods may also be applied to improved and earlier detection of prostatic serum antigen (PSA), a marker for prostate cancer and a marker for recurrence of the cancer post-surgery.

Alternatively, the methods described herein may be used to measure the concentration of a common class target molecule in a sample, such as the IgE class antibodies which are produced in allergic reactions, and further, may be used for the quantification of specific molecules within the common class, such as IgE₁, IgE₂, IgE₃, IgE_x. The advantages of combining the use of specific aptamers directed to a common class of target molecules, or to specific molecules within the common class, with quantitative replicative procedures include the ability to determine the amount of aptamer bound to target molecule in the sample, and thus a quantity of target molecule present in the sample. This approach allows quick, accurate and relatively non-invasive analysis of for example, IgE, for analyzing an allergic reaction, wherein a single blood sample may be used for analysis, rather than 20 or more skin pricks whose results are often ambiguous and merely qualitative at best.

Similarly, exposure of a person to a pathogen triggers an IgG antibody response, such that class IgG antibodies are generated against the specific pathogen. The number and quantity of IgG antibodies present in a person is indicative of prior exposure and potential immunity upon re-exposure to that same pathogen. For example, whereas antibody detection of an infectious organism such as *Mycobacterium tuberculosis*, or a virus such as rubella or smallpox, relies on withdrawing a sample of blood from the person, performing serial dilutions and assaying each dilution individually according to the prior art, the methods described here may be used to quantify antibody titer in a subject in a single reaction.

Additional examples of embodiments of the invention include environmental analysis such as measuring the quantity of growth hormones present in milk; determination of the quantity of pathogenic bacteria such as *E. coli* O1157:H7 in meat or drinking water; or determination of the quantity of a class of antibodies, such as IgE or IgG, in a blood or tissue sample; or the quantity of a specific IgE or IgG antibody in a blood or tissue sample. Thus, the method can be used to determine i) allergic response to various antigens, or ii) an

immunity profile of a patient to show which pathogens they have been exposed to, or iii) contamination of pathogenic organisms in food or drinking supplies, or iv) contamination of food or drinking supplies from pesticides or agricultural livestock food supplements.

Embodiments of the invention provide a method for quantification of target molecules from any of a variety of samples, which does not rely on radioactive reagents, can be detected
5 independent of concentration, and is versatile, fast, and accurate.

The following terms as used here and in the claims are defined as follows:

“Quantitatively assaying a target molecule” means a method which determines a quantity of nucleic acid aptamer using a replicative polymerase reaction, and then relates that
10 quantity of aptamer to a quantity of target molecule.

“Target molecule” includes any macromolecule, including protein, carbohydrate, polysaccharide, glycoprotein, receptor, antigen, antibody, growth factor; or it may be any small organic molecule including a hormone, substrate, metabolite, cofactor, inhibitor, drug, dye, nutrient, pesticide, peptide; or it may be an inorganic molecule including a metal, metal
15 ion, metal oxide, and metal complex; it may also be an entire organism including a bacterium, virus, and single-cell eukaryote such as a protozoon.

“Aptamer” means a natural or non-natural nucleic acid molecule with affinity for a target molecule.

“Natural nucleic acids” means those derived from natural sequences or sources.

20 “Synthetic nucleic acids” means those derived from non-natural sequences, which may contain modified nucleotides, prepared using either chemical or enzymatic synthesis, restriction endonucleases, recombinant techniques, or otherwise.

“Immobilized ligands” mean target molecules, or aptamer-binding regions of target molecules, that have been covalently or non-dissociably bound to a support matrix.

25 “Support matrix” means any resin, bead, including magnetic bead, gel, cellulose, including nitrocellulose filter, silica, alumina, or other solid material.

“Affinity column” means a column for separation of molecules, wherein the separation is achieved because of covalently or non-dissociably bound molecules selecting for

a target molecule.

“A sample obtained from an animal subject” may be a tissue sample, including organ, muscle, bone, connective, fetal, placental, lymphatic, vascular, and neuronal tissue; or it may be a biological fluid sample selected from blood, lymph, urine, sputum, joint, spinal and saliva fluid.

5 “Environmental sample” in the context of this application means non-animal sample, including plant tissue, water, beverages including milk, and industrial waste.

“Hypervariable” means a region of a molecule, most commonly an antibody, subject to inherent instability of sequence, such that mutation occurs frequently in response to exogenous pressures (for example - exposure to a foreign substance, commonly referred to as
10 an antigen -to produce new sequences). “Constant region” means that region of a molecule, most commonly an antibody, that is inherently stable with respect to mutation pressures.

“Exogenous antigen” means any antigen, including allergens, not produced or native to the sample being assayed, for example dust mites, pollen, mold, bee venom, poison ivy extract, and others of such type.

15 “Region” as used herein is a reaction vessel including 1-mL and 500-μL Eppendorf tubes, test tubes, and wells in multi-well plates.

Embodiments of the invention relate to a method and kit for quantitatively assaying one or more target molecules in a sample through use of a nucleic acid aptamer specific for
20 the target molecule. The aptamers are DNA or RNA nucleic acid sequences in the range of 15 - 100 nucleotides, and are prepared by chemical or enzymatic synthesis, or by restriction endonuclease treatment or recombinant technology, and may be modified. Using amplification and enrichment techniques, the aptamers can be selected for binding affinity to any of a number of target molecules.

25 Upon mixing the aptamer with a sample containing target molecule, the aptamer binds to the target molecule and the aptamer-bound target molecule is then separated from the remaining mixture by the use of affinity. Specifically, immobilized ligands, which may be target molecule or portions of the target molecule which bind the specific aptamer, are

utilized to remove any unbound aptamer from the mixture, leaving only aptamer-bound target molecule in the remaining sample mixture. Then, by use of a quantitative replicative procedure, the quantity of aptamer bound to the target molecule is determined, which therefore relates to the quantity of target molecule present in the original sample.

The target molecules may be whole organisms such as bacterium, virus, or single-celled protozoan pathogens; they may be biological macromolecules such as proteins, lipids and carbohydrates; or they may be organic or inorganic molecules such as pesticides, vitamins, and metals. The target molecules may be present in samples of animal tissue, biological fluid, or environmental substances such as plant material, water, beverages, and industrial waste. The immobilized ligands employed in the affinity separation may be attached to a solid support matrix covalently or non-dissociably, and the support matrix may be any material in the art used for such purposes.

The quantitative replicative procedure may involve standard PCR or RT-PCR techniques, in combination with a 5'-nuclease assay involving addition of a fluorogenic probe specific for the aptamer being amplified by PCR or RT-PCR, or in combination with molecular energy transfer (MET) or fluorescence resonance energy transfer (FRET) moieties present on the primers used for amplification. When 5'-nuclease assay is also used, upon binding to the aptamer, the probe, typically labeled with a fluorescent moiety on the 5'-end and a phosphate-capped fluorescent-quenching dye on its 3'-end, is degraded by the 5'-nuclease. As each terminal 5'-nucleotide is released by the nuclease activity, fluorescence occurs and increases with time and amplification of the aptamer. Thus, a real-time measurement of fluorescence increase can be plotted, allowing quantification of aptamer bound to target molecule, which is directly related to quantity of target molecule.

When FRET moieties are used, the primers contain fluorescent donor and acceptor moieties, such that the fluorescence is quenched until primer incorporation into the amplified aptamer product, whereupon quenching stops (because of a conformation change in the primer, for example) and fluorescence is detected. This method has the advantage of allowing direct quantitation of aptamer amplification. (U.S. Patent No. 5,866,336 entitled "Nucleic Acid Amplification of Oligonucleotides with Molecular Energy Transfer Labels and Methods

Based Thereon," Nazarenko, I. A. et al., issued February 2, 1999).

Embodiments of the invention also relate to methods for quantitatively assaying for low abundance target molecules, present at either molar concentrations less than the dissociation constants for their respective specific aptamers, or present in the sample at nanomolar levels or below. The quantitative replicative procedure utilized in embodiments of the invention is capable of amplifying a single nucleic acid aptamer, in theory, and thus is not limited to concentration requirements of other detection methods of the prior art.

In a preferred embodiment, the aptamer is specific for a low abundance target molecule, for example the tumor marker nestin, indicative of a metastatic melanoma. Accordingly, the sample may be human tissue from a biopsy, and the aptamer specific for a region on the nestin tumor marker. The sample tissue and aptamer are mixed together, and all nestin in the sample then binds to the specific aptamer. The sample mixture is then applied to an affinity column or to nitrocellulose filters containing immobilized nestin tumor marker. This step removes all unbound aptamer from the sample mix, leaving only aptamer-bound tumor marker in the solution. Then, quantitative replicative methodology is employed to amplify and quantitate the amount of aptamer bound to the tumor marker. This quantity is then used to determine a quantity of tumor marker originally present in the biopsied tissue sample.

In a second preferred embodiment, the aptamer is specific for a small organic target molecule, exemplified by a pesticide such as one in the synthetic estrogen family. The sample may be an environmental sample such as ground water or plant extract. The aptamer is added to the sample, whereupon all target molecule binds to the aptamer. The remaining unbound aptamer is separated from the sample mixture by application of the mixture to an affinity column containing immobilized pesticide. The eluate from the column then contains only aptamer-bound pesticide. Quantitative replicative procedures are then performed on the eluate, and a quantity determined for the aptamer bound to the pesticide target molecule, which is then used to determine a quantity of pesticide present in the original sample.

In another preferred embodiment, the aptamer is specific for a common region in target molecules of a general common class, exemplified by the class of IgE antibodies. The

common class further includes a plurality of specific target molecules within that common class, for example antigen-specific IgE_x antibodies within the class IgE antibodies. The sample may be human blood, and the aptamer specific for the F_C constant region of the IgE antibody class. Upon mixing, all IgE molecules bind to the aptamer, and unbound aptamer is removed by application of the sample mixture to an affinity column containing the F_C

- 5 constant region of IgE immobilized to the solid support matrix. Thereupon, the eluate from the affinity column, containing only aptamer-bound common class target molecule, is divided into aliquots, and individual aliquots are applied to a second set of separate affinity columns containing immobilized antigen or aptamer specific for the F_{AB} hypervariable region of a number of specific IgE_x antibodies. A quantitative replicative procedure, such as Quantitative
- 10 Polymerase Chain Reaction (QPCR), coupled with 5'-nuclease assay and fluorescently labeled probes, or FRET methodology and fluorescent donor/acceptor pairs, is then performed on the eluate from the second column and on an aliquot of eluate from the first column. The difference in values determined for quantity of aptamer bound to IgE from each column eluate is therefore the quantity for each of the specific IgE_x antibodies present in the sample.

- 15 For ease of understanding, specific sections of the preferred embodiments are now discussed as separate headings.

A. Preparation of Nucleic Acid Aptamers Specific for a Target Molecule

- One method for preparation of nucleic acid aptamers specific for a desired target molecule involves the use of successive repetitive cycles of the following steps: I) production
- 20 of random aptamer sequences; ii) binding of aptamers to a desired target molecule; and iii) partitioning, dissociation, and amplification of aptamers which bind to desired target molecule, thus generating an enriched sample of high-affinity aptamers for the desired target molecule. See e.g. PCT application number WO 91/19813, "Nucleic Acid Ligands" by University of Colorado Foundation, authored by Gold and Tuerk, published December 26,
- 25 1991; PCT application number WO 95/07364, "Nucleic Acid Ligands and Improved Methods for Producing the Same" by Nexagen, Inc., authored by Gold et. al., published March 16, 1995; PCT application number WO 99/07724, "Nucleic Acid Ligands for Blood-Brain and Cerebrospinal Fluid-Blood Barriers by Tissue SELEX" by Nextar Pharmaceuticals,

Inc., authored by Heilig and Gold, published February 18, 1999.

The nucleic acid sequence itself may be single-stranded DNA or RNA, double-stranded DNA or RNA, derive from natural sources and sequences, or be synthesized by chemical or enzymatic methodology from natural or non-natural sequences, and may also contain modified nucleotides.

5 The aptamer used to detect target molecules is both the binding molecule and the reporter entity. This dual role permits quantification of the target molecule by quantifying the aptamer that binds to the target. Moreover, the aptamers have K_D values for their target molecules of 10^{-11} to greater than 10^{-12} molar. Aptamers with such tight binding affinities for their respective target molecules allow quantification of target molecules in samples present at
10 extremely low concentrations.

One preferred embodiment allows quantification of target molecules present in the sample at molar concentrations less than the K_D values for their respective aptamers. Because the aptamers bind their target molecules so tightly, and because the replicative quantitative methods are so sensitive, in theory the aptamer molecule from a single aptamer-target
15 molecule complex can be replicated, amplified and quantitated, thus providing quantification of target molecule present in solution, even at extremely low concentrations.

Another preferred embodiment allows quantification of target molecules present in a sample at molar concentrations greater than or equal to the K_D values for their respective aptamers. Again, the aptamers bind their target molecules very tightly. The presence of
20 excess aptamer permits essentially all target molecules to bind the aptamer. Quantification of the aptamer bound to all target molecules thus provides a reliable quantification of total target molecule originally present in the sample.

B. Target Molecules and Sample

Target molecules, including macromolecules, small organic molecules, inorganic
25 molecules, or whole organisms will be present in a variety of samples to analyze. These samples may be obtained by standard methods known in the art. For example, tissue samples from animals may be obtained by biopsy or simply by removing a slice from an excised organ or deceased specimen, and may be further prepared with homogenization, filtration,

precipitation, or the like; plant tissues may be also require homogenization or extraction treatments. Biological fluid may be obtained by syringe or lancing, and may then be further filtered, centrifuged, or diluted as needed. Similarly, environmental samples may be collected from water sources, industrial waste fluids, and beverages and may require additional treatment as above.

5 C. Immobilized Ligands

Immobilized ligands includes target molecules, or aptamer-binding regions of target molecules, that have been covalently or non-dissociably bound to a support matrix using technology common to one skilled in the art. Peptides and proteins are routinely covalently linked at the terminal amine to a solid support matrix including agarose, silica, and cellulose.

- 10 Many pre-linked materials are even available commercially, for example, agarose-bound concavalin A, specific for thrombin (Vector Laboratories, cat. No. AL-1003). This covalently linked material allows preparation of an agarose affinity column having an immobilized thrombin ligand, wherein the covalently-linked concavalin A on the agarose binds thrombin specifically and non-dissociably, thereby allowing subsequent affinity separation of any
- 15 molecule which is specific for thrombin.

D. Real Time Quantitative Replicative Techniques

Quantitative Replicative Techniques are those which permit real time quantification of a desired target molecule or molecules present in a sample, by comparison to quantification of a nucleic acid aptamer sequence present in the sample vessel and bound specifically to the

20 target molecule. First, the aptamer is replicatively amplified using standard PCR or RT-PCR techniques, such that an amount of amplified aptamer may be quantitated by relationship to the number of replicative cycles required for its detection. The number of cycles required for sufficient replication of the aptamer molecule is related to its low level of abundance. Thus for example if 12 cycles of replication are required to synthesize sufficient copies for

25 detection, the protein is in greater abundance than if 20 or 25 cycles of replication are required. Then, that quantity of aptamer is used to determine the quantity of desired target molecule present in the sample, to which the aptamer was specifically bound in a one to one ratio before amplification.

Various embodiments of the invention utilize a DNA aptamer and one of a set of well-characterized DNA polymerases, for example, a heat stable polymerase such as *Taq* polymerase isolated from the bacterium *Thermus aquaticus*, or a polymerase which is a *Pfu* polymerase isolated from the bacterium *Pyrococcus furiosus*. Both enzymes are available from New England Biolabs, Beverly, MA. Cycles of replicative synthesis can also be
5 obtained with conventional non-heat stable enzymes, by addition of enzyme following each heating step to denature the nucleic acid product, in a series of alternating heating and low temperature synthesis steps. It is necessary in these replicative reactions that primers complementary to each of the 5' and 3' ends of the aptamer nucleic acid be included in the reaction mix, such that synthesis proceeds using the primers for extension to copy the aptamer
10 template, in sufficient quantity that cycles of replication are not limited by the absence of primers. In an embodiment of the invention, the replicative steps are performed using quantitative polymerase chain reaction as described in references infra.

Polymerase reactions typically include all the substrates necessary to replicate the nucleic acid, for example DNA substrates require dATP, dCTP, dTTP, and dGTP, at
15 concentrations sufficient to remain above the K_M of the enzyme throughout a sufficient number of cycles to distinguish the abundances of each of a plurality of proteins being assayed. These concentrations are familiar to one of ordinary skill in the art of synthesis of nucleic acids.

During amplification of the aptamer using standard PCR methods, one method for
20 detection and quantification of amplified aptamer results from the presence of a fluorogenic probe. The probe, which is specific for the aptamer, typically has a 6-carboxyfluorescein (FAM) moiety covalently bound to the 5'-end and a 6-carboxytetramethylrhodamine (TAMRA) or other fluorescent-quenching dye (easily prepared using standard automated DNA synthesis) present on the 3'-end, along with a 3'-phosphate to prevent elongation. The
25 probe is added with 5'-nuclease to the PCR assays, such that 5'-nuclease cleavage of the probe•aptamer duplex results in release of the 5'-bound FAM moiety from the oligonucleotide probe. As amplification continues and more aptamer is replicated by the PCR or RT-PCR enzymes, more FAM is released per cycle and so intensity of fluorescence signal

per cycle increases. The relative increase in FAM emission is monitored during PCR or RT-PCR amplification using an analytical thermal cycler, or a combined thermal cycler/laser/detector/software system such as an ABI 7700 Sequence Detector (Applied Biosystems, Foster City, CA). The ABI instrument has the advantage of allowing analysis and display of quantification in less than 60s upon termination of the amplification reactions.

- 5 Both detection systems employ an internal control or standard wherein a second aptamer sequence utilizing the same primers for amplification but having a different sequence and thus different probe, is amplified, monitored and quantitated simultaneously as that for the desired target molecule (see "A Novel Method for Real Time Quantitative RT-PCR," Gibson, U. et. al., 1996, *Genome Res.* 6:995-1001; Piatak, M. et. al., 1993, *BioTechniques* 14:70-81;
- 10 "Comparison of the BI 7700 System (TaqMan) and Competitive PCR for Quantification of IS6110 DNA in Sputum During Treatment of Tuberculosis," Desjardin, L.e. et. al., 1998, *J. Clin. Microbiol.* 36(7):1964-1976).

In another method for detection and quantification of aptamer during amplification, the primers used for amplification contain molecular energy transfer (MET) moieties,

- 15 specifically fluorescent resonance energy transfer (FRET) moieties, whereby the primers contain both a donor and an acceptor molecule. The FRET pair typically contains a fluorophore donor moiety such as 5-carboxyfluorescein (FAM) or 6-carboxy-4,5-dichloro-2,7-dimethoxyfluorescein (JOE), with an emission maximum of 525 or 546 nm, respectively, paired with an acceptor moiety such as N'N'N'N'-tetramethyl-6-carboxyrhodamine
- 20 (TAMRA), 6-carboxy-X-rhodamine (ROX) or 6-carboxyrhodamine (R6G), all of which have excitation maximum of 514 nm. The primer may be a hairpin such that the 5'-end of the primer contains the FRET donor, and the 3'-end (based-paired to the 5'-end to form the stem region of the hairpin) contains the FRET acceptor, or quencher. The two moieties in the FRET pair are separated by approximately 15-25 nucleotides in length when the hairpin
- 25 primer is linearized. While the primer is in the hairpin conformation, no fluorescence is detected. Thus, fluorescence by the donor is only detected when the primer is in a linearized conformation, i.e. when it is incorporated into a double-stranded amplification product. Such a method allows direct quantification of the amount of aptamer bound to target molecule in

the sample mixture, and this quantity is then used to determine the amount of target molecule originally present in the sample (see U.S. Patent No. 5,866,336, "Nucleic Acid Amplification of Oligonucleotides with Molecular Energy Transfer Labels and Methods Based Thereon," Nazarenko, I. A. et al., issued February 2, 1999).

E. Antibody Structure

5 Antibody molecules generally have two light chains - the L chains - each having about 100 amino acids residues, and two heavy chains - the H chains - each having about 150 amino acid residues, the four chains connected by intramolecular disulfide bonds to form the intact antibody of type H_2L_2 , having a molecular weight of about 500 kDa. In the prototypical "Y"-shaped drawing of the molecule, the inner arms of the Y are comprised of the entire light
10 chains, and are connected by intramolecular disulfide bonds to the amino-termini of the heavy chains. The stem of the Y contains the carboxy-termini of the heavy chains. When cleaved by an endopeptidase, the inner arms of the antibody, which have the antigen binding determinant known as the hypervariable or F_{AB} region, can be separated from the stem which contains the constant F_C (crystalline) region and the determinant that enables the antibody molecule to
15 bind to an antibody receptor on a cell. Because all antibody molecules of a given class, e.g., IgE, have a common F_C region, they can be obtained by separation on this basis, using affinity chromatography for example, whereby an IgE F_C -specific aptamer is immobilized on a solid support matrix and the IgE antibody-containing sample is applied to the column.

Two different sizes of antibody molecules, IgM and IgG, were originally identified by
20 analysis of the size of the proteins. IgM is a pentamer of the H_2L_2 protein molecule, in which each monomer is covalently bonded by disulfide bridges at the F_C end. IgG, and other subsequently identified antibody common classes, including IgE, are monomers of the H_2L_2 structure. IgE level is substantially elevated in subjects having allergies; for example, total IgE blood content can be two, three, or even four orders of magnitude higher in an allergic
25 subject than in a normal subject. In a subject having one or multiple allergies, the excess IgE molecules are populations of polyclonal antibodies, each population having larger than normal quantities, and each population comprising antigen-binding determinants in the F_{AB} for that class of antigens to which the person is sensitive.

Similarly, the IgG fraction from a subject reflecting recent and long-term exposure to antigens throughout the life of the subject is a set of polyclonal populations. Thus a person having been exposed to rubella several decades earlier will retain a very small number of circulating IgG molecules having F_{AB} antigenic determinants specific for a rubella antigen. Recent re-exposure to rubella would enable that person to expand the number of clones of B cells and the number of each clone capable of synthesizing the IgG molecules that can bind the F_{AB} sites to the antigens on the virus. Thus, the diversity of the circulating IgG population reflects the capability of producing a repertoire of immune responses upon re-exposure to an antigen, and the amount of any one species of circulating IgG molecule can indicate how recently a subject has been exposed or re-exposed. Similarly, the amount of any one of a population of antigen specific circulating IgE molecules indicates the extent of allergic response of the subject to the cognate antigen or antigens used in the method.

F. Quantification of Low Abundance Target Molecules

One preferred embodiment allows detection and quantification of low abundance molecules present in a sample. An aptamer specific for the desired target molecule is allowed to combine with the target molecule in a sample, such that all the target molecule binds to the aptamer. Thereon the excess unbound aptamer is separated from the target molecule-bound aptamer using affinity of that aptamer for the target molecule, for example employing an affinity column wherein the target molecule, or the portion of it which binds to the aptamer, is covalently or non-dissociably bound to the support matrix of the column. After applying the sample/aptamer solution to the affinity column, all unbound aptamer will bind to the column, leaving only target molecule-aptamer complexes in the eluate. Upon replicative amplification of the denatured aptamer from the bound complexes, combined with the 5'-nuclease PCR assay, a real time quantification of the aptamer bound to the target molecule can be determined. The quantification of aptamer is based on the number of replicative cycles required for detection as compared to an internal standard, and the quantity of aptamer is then used to determine quantity of target molecule present in the original sample.

Such an embodiment is illustrated in Figures 1 and 2. Fig. 1 illustrates schematically the operation of an embodiment of a method in accordance with the present invention at an

intermediate stage after the addition of aptamers to an aliquot with a sample being analyzed. In this example, we are performing a quantitative assay for target proteins A and B, namely items **106** and **107** respectively, that occur in low abundance in a sample contained in a region **101**, which is here a vessel such as an Eppendorf tube. Also in the sample in Fig. 1 are a number of proteins that are not of interest, namely X and Y, items **103** and **104**, respectively. Also placed in the region is an aptamer **104** that is specific for protein A and an aptamer **105** that is specific for protein B. These aptamers are present in relatively larger abundance in the region than the target proteins, with the result that substantially all of proteins A and B in the region form complexes with their respective aptamer, and excess uncomplexed quantities of each of the aptamers for each of the target proteins remain in the sample.

Fig. 2 shows how the materials in Fig. 1 may be further treated to remove excess uncomplexed aptamer by affinity. In this example, a column **204** has each of the target proteins A and B immobilized in regions **201** and **202** respectively, in a manner known in the art. The immobilized proteins are present in sufficient abundance to form complexes with all uncomplexed aptamer molecules in the sample in vessel **101** of Fig. 1. In this manner when the sample from vessel **101** runs through the column **204**, the uncomplexed aptamer molecules are removed from solution. In the resulting eluate mixture in collection region **203**, all aptamer molecules present are bound to their respective target proteins.

Because the aptamers are nucleic acids, each aptamer in the collection region **203** can be assayed using a quantitative replicative procedure, such as a quantitative polymerase chain reaction procedure (QPCR). Because each aptamer assayed is complexed to its respective target protein in the collection region **203**, the number of molecules of a given aptamer present in collection region **203** corresponds to the number of the corresponding target molecules in the same region and therefore in the sample.

G. Quantification of a Common Class Target Molecule and of Specific Target Molecules Within the Common Class.

A second preferred embodiment is directed towards quantification of a common class of molecules present in a sample. Specifically, the common class of target molecule is an antibody, more specifically the antibody class is IgE, and more specifically the target molecules are individual antigen-specific IgE_x antibodies within the common class of IgE

antibodies, for example IgE_1 , IgE_2 , IgE_3 , IgE_x . Aptamers are selected with specificity for the F_C constant region of the IgE class of antibodies. Other aptamers are selected with specificity for the F_{AB} hypervariable regions of specific IgE_x antibodies within the common class. Alternatively, antigens can be used as the molecules with specificity for the F_{AB} hypervariable region of the antibody.

5 The aptamers specific for the F_C constant region of the IgE target molecules are allowed to mix with all the IgE antibodies in a sample such that all the common class target molecules in the sample bind to the aptamers. The sample may be human blood, or blood serum, for example. Then, an aliquot of this sample mixture is applied to an affinity column containing immobilized F_C constant region of IgE, permitting separation of all unbound

10 aptamer remaining in the sample mixture. The eluate from this first column thus contains target IgE molecules only bound to aptamer. An aliquot of the eluate is then applied to a second affinity column containing immobilized aptamer or antigen specific for the F_{AB} hypervariable region of a specific IgE_x antibody. This second column permits removal of specific IgE_x antibodies from the sample mixture, leaving all aptamer-bound IgE common
15 class molecules in the eluate except those which bind the specific IgE_x aptamer or antigen immobilized on the second column. Quantitative replicative procedures are then performed on aliquots of eluate from each of the first and second affinity columns, and the difference in quantification of aptamer determined for each eluate aliquot is used to determine the quantity of specific IgE_x antibody.

20 In a similar preferred embodiment, the first target molecule is again a common class of molecules, specifically antibodies, more specifically the IgE class of antibodies, and more specifically individual IgE_x antibodies within the IgE class. Aptamers are again selected for specificity to the constant region of the IgE class of antibodies, and other aptamers are selected for specificity to the hypervariable regions of specific IgE_1 , IgE_2 , IgE_3 , IgE_x
25 antibodies within the common class, or specific antigens are used. In this embodiment however, after allowing aptamer to mix and bind to the common class IgE antibodies in the sample, the first column is run simultaneously with the second column, but on two different aliquots from the same sample/aptamer mixture. Column one contains both constant region

of IgE class antibody *and* aptamer or antigen specific for the hypervariable region of a specific IgE_x antibody immobilized on the affinity column. Column two contains only immobilized constant region of IgE class antibody. Quantitative replicative procedures are then run on aliquots from the eluate of each of the two columns. The difference in quantification values of aptamer determined for each eluate is then used to determine the quantity of specific IgE_x antibody originally present in the sample mixture.

Fig. 3 relates to such an embodiment of the present invention, specifically for quantifying the antibody response of a subject to one or more antigens. The method of this embodiment relies on the fact that all antibody molecules of a given common class can be collected by virtue of sharing a common F_c region, while all IgE_x antibody molecules specific for a given antigen can be collected by virtue of affinity for that antigen. Fig. 3 illustrates schematically the operation of an embodiment at an intermediate stage after the addition of aptamers to a region with a sample being analyzed to form antibody-aptamer complexes in a common class mixture.

Fig. 3 shows a region **101**, realized here as a vessel, in which there is included a sample of tissue (such as blood) from a subject having antibodies of several different common classes including IgE, item **102**, symbolized by an E, IgG, item **103**, symbolized by a G. Some of the IgE antibodies have specificity for a first antigen, and these IgE antibodies are shown as E₁ in Fig. 3. Some of the IgE antibodies have specificity for a second antigen, and these IgE antibodies are shown as E₂ in Fig. 3. Finally, some of the IgE antibodies have specificity for a third antigen, and these IgE antibodies are shown as E₃ in Fig. 3. To the vessel **101** has been added an aptamer **104** that binds generally to IgE antibodies regardless of the antigen for which each IgE antibody has specificity. Aptamer has been added in greater abundance than the IgE antibody **102**, so that substantially all of the IgE antibodies have formed complexes with aptamer. The resultant mixture in Fig. 3 is referred to as a common class mixture. A measured amount of aptamer is added to the vessel, so that the unbound aptamer **104** provides an inverse measure of the amount of the common class of total IgE present in the subject.

Fig. 4 shows schematically the effect of separation, from aliquots of the common class mixture, of antigen-specific antibody-aptamer complexes. The first antigen **23** (Ag₁) ,

namely the antigen for which E_1 antibody is specific, is immobilized in column **21**. Similarly, the second antigen **24** (Ag_2), namely the antigen for which E_2 antibody is specific, is immobilized in column **22**. The F_C constant region of IgE is immobilized on column **26**. A separate aliquot of the common class mixture of Fig. 3 is run through each of the columns **21** or **22**. The effect of the first antigen in column **21** is to remove from the mixture only the E_1 antibody-aptamer complexes. Similarly, the effect of the second antigen in column **22** is to remove from the mixture only E_2 antibody-aptamer complexes. The effect of the immobilized F_C region of IgE in column **26** is to remove all unbound aptamer, leaving only IgE_x-bound aptamer in the eluate of collection chamber **28**. If the common class mixture is run through columns **21** or **22**, and the resultant flow-through is collected in a collection chamber **25** or **27**, respectively, what remains is a mixture including the uncomplexed aptamer **104**, antibody molecules of the same common class which lack specific affinity for the first or second antigens, and antibody of any other class which lack specific affinity for the antigen, these being collected along with the unbound aptamer.

Quantification of the specific antibodies E_1 or E_2 may be quantified in a number of different ways. In a first embodiment, uncomplexed aptamer **104** is removed from the common class mixture using a column, **26**, with immobilized F_C region of IgE. After removal of this uncomplexed aptamer, the total quantity of aptamer in the resulting column flow-through (eluate) in collection chamber **28**, which in the mixture is complexed with all IgE, is a measure of total IgE concentration in the original common class mixture and therefore in the tissue sample. QPCR techniques are applied to determine the amount of aptamer and therefore of IgE.

Then, an aliquot of the eluate from either column **21** or **22** is applied to column **26**. The amount of antibody-bound aptamer remaining in the eluate after application of sample aliquots to column **21** or **22**, followed by column **26**, is again determined using QPCR techniques. The difference between quantity of aptamer in this second eluate (from sequential application of sample to column **21** or **22** followed by column **26**) and quantity of aptamer in the eluate of column **26** alone is attributable to IgE₁ or IgE₂ that has bound to its specific antigen in either column **21** or **22**, and therefore is a measure of specific IgE₁ or IgE₂ antibody

originally present in the sample.

Alternatively, an aliquot of the common class mixture can be applied to a column (not shown) having both immobilized IgE and specific antigen IgE_x, to bind both unbound aptamer and antigen-specific IgE_x bound to aptamer. The difference by QPCR of aptamer in the eluate of this column and from a column having only bound IgE is a measure of the
5 quantity of the IgE_x present in the original common class mixture, and hence the tissue sample.

In another embodiment, a measurement is made directly on the antibody-aptamer that has remained bound to the immobilized specific antigen in each column **21** and **22**. The column is eluted with a denaturing solution, and a QPCR assay may be performed on the
10 eluate or a derived fraction of the eluate. For example, the column can be eluted using a buffer having a high or a low pH, and the eluate can be neutralized prior to a qualitative replicative assay. Thereupon, quantitative replicative procedure is performed such that the aptamer molecules which are complexed to the shared sites located in the F_C region of a common class of antibody molecules can be accurately and repeatedly replicated by one or
15 more nucleic acid polymerases or other enzymes of nucleic acid synthesis.

Prior to that replication, however, the mixture of all species within the common class is further fractionated by collecting the total number of antibody-aptamer complexes having a certain antigen specificity, as illustrated in Fig. 3. This is possible because the antigen-specificity is determined by amino acid residues at the other end of the antibody molecule, the
20 F_{AB} region. An aliquot of the initial mixture of the tissue, for example, blood (including a blood fraction such as plasma or serum) is affinity purified by virtue of affinity for molecules in a purified preparation of the antigen. This can be achieved as illustrated in Fig. 4.

The number of cycles required for sufficient replication of the aptamer molecule is a measure of its level of abundance.

25 H. Pluralities of fractions obtained in the method

Multiple levels of pluralities can be utilized. A tissue sample can be fractioned prior to use, for example, blood cells and clotting proteins can be removed, producing derivative fractions such as serum and plasma. Further, each of several aliquots of the common class

mixture of Fig. 3 containing aptamer bound to all of the molecules of a common class, and excess aptamer, can be further fractionated to obtain the subclasses of molecules having antigen-binding determinants for each of a plurality of antigens. For example, a tissue sample of a subject can first be exposed to an aptamer specific for IgE, then aliquots of the resulting common class mixture can be exposed, for example, to each of a dust mite antigen, to an antigen of cat saliva, and to an antigen found in human collagen.

In each of these antigen-based purifications, the aptamer-antibody complex that binds to the antigen can be isolated, and the aptamer can be subjected to a replicative procedure to quantify the amount of the complex so isolated. The result can be compared with the total aptamer present in the original mixture in Fig. 3, with the amount that binds and that fails to bind the antigen and is collected as a “flow-through” of eluate from the bottom of each column. Thus, in the instance that only a small amount of complex binds to a column, an accurate and significant reading of this small bound amount can be made using the replicative procedure. If, however, a large amount binds to the antigen, an accurate assessment of the amount in the eluate that flows into a collection chamber **25** in Fig. 4 can be obtained.

All the values can be compared to normative data obtained from other subjects, or from earlier samples obtained from the same subject, or from comparison to the amount of the common class mixture bound to IgE. A plurality of different antigens can be used simultaneously to assay the sample or samples from the subject. Different family members can be tested, and samples can be obtained over the time course of administration of a particular drug or drugs.

What is claimed is:

1. A method for quantitatively assaying one or more target molecules in a first sample, comprising:

- 5 (a) adding to the first sample, a preparation of a nucleic acid aptamer specific for each target molecule;
- (b) allowing substantially all of the target molecules in the first sample to bind with the aptamers;
- 10 (c) separating unbound aptamers from the first sample by contacting the sample of step (b) with immobilized ligands wherein the ligands bind to the unbound aptamers;
- (d) recovering a second sample containing the aptamer bound to target molecules; and
- 15 (e) using a quantitative replicative procedure to determine a quantity related to the concentration of the aptamer in the second sample and therefore related to the concentration of target molecules in the first sample.

2. A method according to claim 1, wherein the nucleic acid aptamer is selected from the group consisting of natural or synthetic single-stranded DNA, double-stranded DNA, single-stranded RNA, double-stranded RNA and chemical modifications thereof.

3. A method according to claim 1, wherein the target molecule is present in the sample at molar concentrations less than their dissociation constants with respect to the aptamers.

25 4. A method according to claim 1, wherein the target molecule is present in the sample at molar concentrations equal to or greater than their dissociation constants with respect to the aptamers.

5. A method according to claim 1, wherein the target molecule are low abundance molecules.

6. A method according to claim 1, where the target molecules include biological macromolecules.

5

7. A method according to claim 6, wherein the biological macromolecules are selected from the group consisting of a protein, a lipid, a polysaccharide or combinations thereof.

10 8. A method according to claim 1, wherein the target molecules include small organic molecules.

9. A method according to claim 8, wherein the small organic molecules are selected from a group consisting of antibiotics, vitamins, steroids, and pesticides.

15

10. A method according to claim 1, wherein the target molecules include inorganic molecules.

11. A method according to claim 10, wherein the inorganic molecules are metal.

20

12. A method according to claim 11, wherein the metal is selected from a group consisting of metal ions, metal oxides, and metal complexes.

13. A method according to claim 1, wherein the first sample is obtained from an animal subject.

25

14. A method according to claim 13, wherein the sample is selected from the group consisting of organ tissue, muscle tissue, bone tissue, connective tissue, fetal, placental, lymphatic tissue, vascular tissue, neuronal tissue.

15. A method according to claim 1, wherein the sample is a biological fluid selected from blood, lymph, urine, sputum, joint including spinal fluid, and saliva.

16. A method according to claim 1, wherein the first sample is an environmental sample.

5

17. A method according to claim 16, wherein the environmental sample is obtained from a plant, water, food beverages including milk, and industrial waste.

18. A method according to claim 1, wherein the immobilized ligand is
10 immobilized on a support matrix selected from the group consisting of resins, beads, including magnetic beads, gels, cellulose and silica.

19. A method according to claim 1, wherein the immobilized ligand is immobilized on an affinity column.

15

20. A method according to claim 1, wherein the quantitative replicative procedure is a quantitative polymerase chain reaction.

21. A method according to claim 1, wherein measuring the amount of aptamer
20 bound to the target molecule further includes denaturing the aptamer so as to separate the nucleic acid from the target molecules.

22. A method according to claim 21, wherein oligonucleotide primers are added to the sample after denaturing the aptamer from the target molecules.

25

23. A method according to claim 22, wherein determining the concentration of aptamer includes determining a number of replicative cycles.

24. A method according to claim 6, wherein the target molecules are antibodies.

25. A method according to claim 24, wherein the target molecules include IgE.

26. A method according to claim 1, wherein the target molecules include a plurality of antibody molecules belonging to different subclasses characterized by a difference in the hypervariable region of the antibody.

5

27. A method according to claim 1, wherein the target molecules are a subclass of an antibody having a characteristic hypervariable region.

28. A method according to any of claims 24-27, wherein the aptamer binds to a
10 constant region of the antibody and wherein the immobilized ligand is the constant region of the antibody for removing unbound aptamer from the sample.

29. A method according to claim 24, wherein the second sample contains antibody-bound aptamer, the second sample being divided into a plurality of aliquots, a first
15 aliquot of the second sample being assayed using a quantitative replicative technique to determine an amount of antibody in the first sample.

30. A method according to claim 29, further comprising:

- 20 (a) contacting a second aliquot of the second sample with an immobilized ligand for binding an antibody with a first hypervariable region; wherein the antibody with a first hypervariable region is one of the target molecules in the first sample;
- (b) recovering a third sample containing the aptamer bound to target molecules excluding the antibody with the first hypervariable region;
- 25 (c) assaying the aptamer concentration in the third sample using the quantitative replicative technique, so as to determine a difference in an amount of aptamer in the second sample and the third sample; and
- (d) obtaining a measure of an amount of the antibody with the first hypervariable region in the first sample from the difference.

31. A method according to claim 29, further comprising:

- 5
- (a) contacting a plurality of aliquots of the second sample with an immobilized ligand wherein the ligand is immobilized by attachment to a substrate in a single chamber, or to multiple substrates wherein each substrate is contained in a separate chamber, each immobilized ligand having a specificity for an antibody with a different hypervariable site;
 - (b) recovering a third sample containing the aptamer bound to target molecules excluding the antibody bound to immobilized ligand;
 - (c) assaying the aptamer concentration in the third sample using the quantitative replicative technique, so as to determine a difference in an amount of aptamer in the second sample and the third sample; and
 - 10 (d) obtaining a measure of the antibody with the hypervariable region in the first sample from the difference.

15 32. A method according to claims 30 and 31, wherein the ligand is a specific antigen.

33. A method according to claim 1, wherein the ligand is a reagent having the aptamer-binding characteristics of the target molecule.

20 34. A method according to claim 30 and 31, wherein the antibody is IgE.

35. A method for quantitatively evaluating *in vitro* an antibody response of a subject to an antigen, the method comprising:

- 25
- (a) obtaining a sample from the subject and an aptamer for binding generally to all antibodies of a common class;
 - (b) allowing substantially all of such antibodies in the sample to bind the aptamer in a common class mixture, so that the common class mixture includes antibody-aptamer complexes;

(c) using antigen-antibody affinity binding to separate from an aliquot of the common class mixture those of the antibody-aptamer complexes having antibodies specific to the antigen, to produce (I) an antigen-specific antibody-aptamer complex and (ii) a difference mixture; and

(d) using a quantitative replicative procedure to determine a quantity
5 related to the concentration of the antigen-specific antibody-aptamer complex relative to the concentration of the antibody-aptamer complexes in the common class mixture, and therefore related to the response of the subject to the antigen.

36. A method for quantitatively evaluating *in vitro* the response of a subject to a
10 plurality of different antigens, the method comprising:

(a) obtaining a sample from the subject and adding an aptamer for binding generally to all antibodies of a common class in the tissue;

(b) allowing substantially all of such antibodies in the sample to form a complex with the aptamer in a common class mixture, so that the
15 common class mixture includes antibody-aptamer complexes;

(c) using antigen-antibody affinity binding to separate, from each of a plurality of aliquots of the common class mixture, those of the antibody-aptamer complexes having antibodies specific to a different one of the antigens, to produce with respect to each different antigen
20 (i) an antigen-specific antibody-aptamer complex and (ii) a difference mixture; and

(d) using a quantitative replicative procedure to determine a quantity related to the concentration of each different antigen-specific antibody-aptamer complex relative to the concentration of the antibody-aptamer complexes in the common class mixture,
25 and therefore related to the response of the subject's tissue to each of the different antigens.

37. A method according to each of claims 35 and 36, wherein the sample is blood.

38. A method according to claim 35, wherein the antigen is an exogenous

allergen, and wherein the class of antibodies is IgE.

39. A method according to claim 36, wherein each of the antigens is a different exogenous allergen and the class of antibodies is IgE.

5 40. A method according to claim 35, wherein the antigen is associated with an infectious disease, and the class of antibodies is IgG.

41. A method according to claim 36, wherein each of the antigens is associated with an infectious disease, and the class of antibodies is IgG.

10

42. A method according to any of claims 35-41, wherein the quantitative replicative procedure utilizes a quantitative polymerase chain reaction procedure and includes determining the number of replicative cycles to produce a threshold indication.

15

43. A method according to claim 38, wherein the response of the subject is an allergic response to an allergen.

44. A kit for determining the allergic response of a subject to an allergen; comprising:

20

- (a) an aptamer specific for a common class of IgE and a plurality of aptamers specific for individual allergens;
- (b) a plurality of reaction chambers for holding individual aliquots of a sample taken from the subject after binding the common class of antibody and removing unbound aptamer;
- 25 (c) an immobilized antibody for binding unbound aptamer of the common class prior to aliquoting the sample, and allergen for binding specific antibodies; and
- (d) means for quantitatively replicating the aptamers of the common class of IgE and for the aptamer-IgE complexes not bound to the allergen.

02331/00103 120102 1




Figure 1




Figure 2




Figure 3

Docket No.
2331/111

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

SYSTEM AND METHOD FOR QUANTITATIVE ASSAY FOR LOW ABUNDANCE MOLECULES

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International
Application Number _____
and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

<u>60/139,647</u>	<u>June 17, 1999</u>
(Application Serial No.)	(Filing Date)
<u>60/139,697</u>	<u>June 17, 1999</u>
(Application Serial No.)	(Filing Date)
<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

<u> </u>	<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
<u> </u>	<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
<u> </u>	<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Bruce D. Sunstein	27,234	Elizabeth Morano	42,904
Samuel J. Petuchowski	37,910	Sonia K. Guterman	44,729
Robert M. Asher	30,445	Keith J. Wood	45,235
Timothy M. Murphy	33,198	Karen A. Buchanan	37,790
Harriet M. Strimpel	37,008		
Jeff T. Klayman	39,250		
Steven G. Saunders	36,265		
Herbert A. Newborn	42,031		
John Stickevers	39,387		
Jean M. Tibbetts	43,193		
Jay Sandvos	43,900		

Send Correspondence to: **Harriet M. Strimpel, D. Phil.**
Bromberg & Sunstein LLP
125 Summer Street,
Boston, MA 02110

Direct Telephone Calls to: *(name and telephone number)*
Harriet M. Strimpel, D. Phil. (617) 443-9292

Full name of sole or first inventor John C. Cheronis	
Sole or first inventor's signature	Date
Residence 24011 Pleasant Road, Conifer, CO 80433	
Citizenship US	
Post Office Address Same as Residence	

Full name of second inventor, if any David Trollinger	
Second inventor's signature	Date
Residence 5375 Desert Mountain Court, Boulder, CO 80301	
Citizenship US	
Post Office Address Same as Residence	